Changes in the Incidence and Predictors of Human Immunodeficiency Virus-Associated Dementia in the Era of Highly Active Antiretroviral Therapy
Ann Neurol 63:213-221, Bhaskaran,K.,et al, 2008
An Update on Primary Drug Therapies for Alzheimer Disease
Arch Neurol 54:1406-1409, Knopman,D.S.&Morris,J.C., 1997
Treating Hearing Loss with Hearing Aids for the Prevention of Cognitive Decline and Dementia
Neurol 106:e214572, Cribb,L.,et al, 2026
Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Hearing Aids and Cochlear Implants in the Prevention of Cognitive Decline and Dementia-Breaking Through the Silence
JAMA Neurol 80:127-128, Denham,M.W.,et al, 2023
Recent Advances in the Diagnosis and Management of Cluster Headache
BMJ 376:e059577, Schindler, E. & Burish, M.J., 2022
Spina Bifida
NEJM 387:444-450, Iskandar, B.J. & Finnell, R.H., 2022
Sport Associated Dementia
BMJ 372:N168, Stewart, W., 2021
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Stroke
Lancet 389:641-654, Hankey, G.J., 2017
CGRP - The Next Frontier for Migraine
NEJM 377:2190-2191, Hershey, A.D., 2017
Intervention Versus Aggressive Medical Therapy for Cognition in Severe Asymptomatic Carotid Stenosis
AJNR 37:1889-1897, Lin, C.J.,et al, 2016
Antiamyloid Therapy for Alzheimers Disease - Are We on the Right Road?
NEJM 370:377-378, Karran, E. & Hardy, J., 2014
Intracranial Atherosclerosis
Lancet 383:984-998, Qureshi, A. & Caplan, L.R., 2014
Aggressive Medical Therapy Alone is Not Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2955-2956, Brown, M.M., 2013
Aggressive Medical Therapy Alone is Adequate in Certain Patients with Severe Symptomatic Carotid Stenosis
Stroke 44:2957-2958, Chaturvedi, S.,et al, 2013
Cerebral Amyloid Angiopathy
eMedicine, Jan, Menon, R.S., 2012
Sporadic Cerebral Amyloid Angiopathy Revisited: Recent Insights Into Pathophysiology and Clinical Spectrum
JNNP 83:124-137, Charidimou,A.,et al, 2012
Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimers Disease
NEJM 367:864-866, Gandy, S., 2012
Effect of Vaccines on Bacterial Meningitis Worldwide
Lancet 380:1703-1711,1623, McIntyre, P.,et al, 2012
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
Stroke 43:3442-3453, Furie, K.,et al, 2012
A New Landscape for Stroke Prevention in Atrial Fibrillation
Stroke 42:3316-3322, Banerjee, A.,et al, 2011
Antiretroviral Prophylaxis: A Defining Moment in HIV Control
Lancet 378:e23-25, Karim, S.S. and Karim, Q.A., 2011
Use of Angiotension Receptor Blockers and Risk of Dementia in a Predominantly Male Population: Prospective Cohort Analysis
BMJ 340:141-147, 111, Li,N.-C.,et al, 2010
Risk of Dementia and AD with Prior Exposure to NSAIDs in an Elderly Community-Based Cohort
Neurol 72:1899-1905,1884, Breitner,J.C.S.,et al, 2009
Safety and Efficacy of Galantamine in Subjects with Mild Cognitive Impairment
Neurol 70:2024-2035, Winblad,B.,et al, 2008
A Randomized Placebo-Controlled Trial of Ginkgo Biloba for the Prevention of Cognitive Decline
Neurol 70:1807-1817,1730, Dodge,H.H.,et al, 2008
Phase 2 Safety Trial Targeting Amyloid � Production With a ?-Secretase Inhibitor in Alzheimer Disease
Arch Neurol 65:1031-1038, Fleisher,A.S.,et al., 2008
Stroke and Multi-Infarct Dementia as Presenting Symptoms of Giant Cell Arteritis: Report of 7 Cases and Review of the Literature
Medicine 87:335-344, Solans-Laque,R.,et al, 2008
Low Dose Aspirin and Cognitive Function in the Womens Health Study Cognitive Cohort
BMJ 334:987-990,961, Kang,J.H.,et al, 2007
The Neuroprotective Effects of Caffeine: A Prospective Population Study (the Three City Study)
Neurol 69:536-545, Ritchie,K.,et al, 2007
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Delirium in Older Persons
NEJM 354:1157-1165, Inouye,S.K., 2006
Behavioral Effects of Memantine in Alzheimer Disease Patients Receiving Donepezil Treatment
Neurol 67:57-63, Cummings,J.L.,et al, 2006
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
NEJM 352:2379-2388,2439, Petersen,R.C.,et al, 2005
Statin Use and the Risk of Incident Dementia
Arch Neurol 62:1047-1051, Rea,T.D.,et al, 2005
Lipid Lowering Agents Are Associated With a Slower Cognitive Decline in Alzheimers Disease
JNNP 76:1624-1629, Masse,I.,et al, 2005
Reduced Risk of Alzheimer Disease in Users of Antioxidant Vitamin Supplements
Arch Neurol 61:82-88, Zandi,P.P.,et al, 2004
Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women
JAMA 291:2947-2958,3005, Shumaker,S.A.,et al, 2004
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Arch Neurol 60:203-208, Luchsinger,J.A.,et al, 2003
Blood Pressure-Lowering for Secondary Prevention of Stroke: ACE Inhibition Is Not the Key
Stroke 34:1334-1335,1335, Bath,P., 2003
Blood Pressure--Lowering for Secondary Prevention of Stroke: ACE Inhibition Is the Key
Stroke 34:1333-1334,1334, Anderson,C., 2003
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women
JAMA 289:2651-2662,2717, Shumaker,S.A.,et al, 2003
Leisure Activities and the Risk of Dementia in the Elderly
NEJM 348:2508-2516, Verghese,J.,et al, 2003
Consumption of Fish and n-3 Fatty Acids and Risk of Incident Alzheimer Disease
Arch Neurol 60:940-946,923, Morris,M.C.,et al, 2003
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003